PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

KORU Medical Systems, Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from KORU Medical Systems, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.

What stands out

  • Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.

Cash quality

Profit Cash Ratio

—

Loss-making or profit too small

Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.

Self-Funding Ratio

-1.5×

Over the last 3 years operating cash was negative while the company kept spending on investment (capex).

Higher than 60% of Healthcare companies in United States.

Cash Locked Ratio

$19

For every $100 of sales, $19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.

Less money tied up than 60% of Healthcare companies in United States.

Growth quality

Steadiness Ratio

3/3 · 2/3

Sales grew in 3 of the last 3 years; profit grew in 2 of 3.

Steadier than 85% of Healthcare companies in United States.

Growth Efficiency Ratio

$46

Sales grew 47% in 3 years; of every extra $100 of sales, $46 became extra profit.

Higher than 68% of Healthcare companies in United States.

Asset Productivity Ratio

+47% / -33%

In 3 years sales changed by +47% while total assets changed by -33%. Sales grew faster than assets.

Balance-sheet strength

Debt Due Cover Ratio

0.9×

Debt due within a year is covered 0.9 times by its yearly operating cash.

Higher than 71% of Healthcare companies in United States.

Cash Cushion Ratio

+4%

Cash, after subtracting all debt, equals 4% of its market value (net cash).

Lower than 60% of Healthcare companies in United States.

Tangible Assets Ratio

98%

Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.

More tangible than 82% of Healthcare companies in United States.

Tangible Net Worth Ratio

96%

Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.

More tangible than 83% of Healthcare companies in United States.

Shareholders

Shareholder Slice Ratio

+2%

Share count rose 2% in 3 years, so each share's slice of the company became smaller.

Smaller rise in share count than 80% of Healthcare companies in United States.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (12)

KORU Medical Systems, Inc. made a loss over the last year. KORU Medical Systems, Inc. owes $0.35 for every $1 it owns. KORU Medical Systems, Inc. made a loss in each of the last two years.

Compared with Healthcare companies in United States · latest annual results Dec 2025.

P/E ratio

Loss

KORU Medical Systems, Inc. made a loss over the last year, so its P/E ratio is not meaningful.

P/B ratio

7.82

The share price is 7.82 times KORU Medical Systems, Inc.'s book value per share, higher than 82% of Healthcare companies in United States.

Market cap

$141 M

The total market value of all of KORU Medical Systems, Inc.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.

Net worth (book value)

$18 M

What KORU Medical Systems, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).

Book value per share

$0.39

Net worth divided by the number of shares. The share price of $3.08 is 7.8 times this, which is the P/B above.

Return on equity (ROE)

-10.5%

KORU Medical Systems, Inc. lost 10.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.

Owes vs Owns

0.35×

KORU Medical Systems, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.

Dividend yield

None

KORU Medical Systems, Inc. does not currently pay a dividend.

Revenue growth

+22%

Revenue rose 22% in the year to Dec 2025, and grew 14% a year on average over 3 years.

Profit growth

Loss

KORU Medical Systems, Inc. made a loss in each of the last two years.

Profit margin

-6.4%

KORU Medical Systems, Inc. lost $6 for every $100 of revenue.

Cash vs debt

Net cash

KORU Medical Systems, Inc. held $5 M more cash than debt (net cash) at Dec 2025.

Questions

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For KORU Medical Systems, Inc.: $141 M ÷ $18 M (30 Jun 2026) = 7.8.

What is KORU Medical Systems, Inc.'s return on equity?

KORU Medical Systems, Inc. lost 10.5% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.

How much does KORU Medical Systems, Inc. owe compared with what it owns?

KORU Medical Systems, Inc. owes $0.35 for every $1 it owns (low), lower than 55% of Healthcare companies in United States.

Does KORU Medical Systems, Inc. pay a dividend?

No. KORU Medical Systems, Inc. does not currently pay a dividend.

Is KORU Medical Systems, Inc.'s revenue growing?

Revenue rose 22% in the year to Dec 2025, and grew 14% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.